CRIS

Curis, Inc.

A clinical-stage biotechnology company in Lexington, Massachusetts, developing emavusertib, an oral pill for blood cancers like primary central nervous system lymphoma and chronic lymphocytic leukemia. Formed in 2000 from the merger of three Boston-area biotech firms, its logo carries a musical fermata—a symbol that holds a note—reflecting its goal of prolonging life and curing cancer. Curis also helped develop Erivedge, an approved treatment for advanced basal cell carcinoma.